期刊
CURRENT MEDICINAL CHEMISTRY
卷 21, 期 14, 页码 1618-1630出版社
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/09298673113209990223
关键词
Anti-cancer peptides; drug resistance; small molecule inhibitors; targeted cancer therapy
资金
- departments of Obstetrics/Gynecology and Pathology of Downstate Medical Center
- Health Science Center at Brooklyn
- State University of New York
Since the introduction of chemotherapy in cancer therapy, development of resistance to every new therapeutic has been the universal experience. The growing understanding of cancer genomics, cancer-associated signal transduction pathways, and key protein drivers of cancer has enabled cancer biologists and medicinal chemists to develop targeted molecules to interfere with these pathways to tackle drug resistant cancers. However, to the dismay of oncologists, the clinical use of many of these tools has once again brought to the forefront the inevitable challenge of drug resistance. It is now understood that cancer resistance to different therapies involves multiple challenges that encompass the cancer cell itself as well as host physiology. This review presents small molecule inhibitors and peptides as two therapeutic approaches in anti-cancer drug development. Resistance to selected samples of these novel therapies is described in the context of cell autonomous resistance, the contributions of the tumor microenvironment, and germ line factors. For each approach, advantages and disadvantages are discussed on how to better overcome the inevitable challenge of resistance in cancer treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据